iLite mVEGF (-) Target Assay Ready Cells

$720.00

The iLite ADCC Target mVEGF (-) Assay Ready Cells can be used for assessing the possibility of an anti-VEGF antibody-drug inducing ADCC. The iLite ADCC Target mVEGF (-) Assay Ready Cells are for research use only and not to be used for diagnostic procedures.

iLite mVEGF (-) Target Assay Ready Cells

iLite mVEGF (-) Target Assay Ready Cells are Developed and Manufactured by Svar Life Science

The Eagle Bioscience’s iLite mVEGF (-) Target Assay Ready Cells are intended for the:

  • Quantification of anti-mVEGF ADCC activity.

Content: >250 μL of Assay Ready Cells suspended in cryoprotective medium from Gibco.

Receipt and Storage: Upon receipt confirm that adequate dry ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C (do not store at any other temperature) and are stable as supplied until the expiry date shown. Cells should be used within 30 min of thawing and should be diluted immediately after thawing – note that delayed addition of the diluted cell suspension to the plate might cause a shift in EC50 value.

For Research Use Only


Key Benefits of iLite Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Description

iLite mVEGF (-) Target Assay Ready Cells are based on a human embryonic kidney cell line, HEK2931, and have been genetically engineered to not express any membrane-bound Vascular Endothelial Growth Factor (VEGF). The cells are for use as internal controls together with iLite® ADCC Effector (V) Assay Ready Cells and iLite mVEGF (+) Target Assay Ready Cells for measuring the ADCC activity of anti-VEGF antibodies.

[1] The HEK-293 cell line has been used under a license obtained from AdVec Inc.


Related Products

iLite ADCC Target HER2+ Assay Ready Cells
iLite ADCC Target mTNF-alpha (+) Assay Ready Cells
iLite G-CSF Assay Ready Cells

Documents

Product Manual


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Additional Information

Background


Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, mainly Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells results in activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, inducing apoptosis of the targeted cell (1). ADCC is one mode of action for several antibodies targeting membrane bound antigens such as rituximab (target CD20) and trastuzumab (target HER2) while therapeutics directed to soluble targets mainly work by inhibiting the binding of the antigen to its receptor, such as infliximab (target TNF-alpha) and bevacizumab (target VEGF. Vascular Endothelial Growth Factor (VEGF) is a signalling protein which is involved in both normal vascular growth and pathological angiogenesis (2). VEGF is secreted from cells and a large portion can be found bound to the extra cellular matrix (ECM) (3). Anti-VEGF treatment is widely used as cancer therapy, the drug inhibits angiogenesis and thereby limits the tumours growth and ability to metastasize (4). In 2004, Bevacizumab was the first anti-VEGF therapeutic antibody to be approved for treatment in metastatic colon cancer. Anti-VEGF therapeutics act as inhibitors of VEGF and its receptor interactions. Today, it is additionally approved for several other cancer forms (5). Bevacizumab biosimilar agents are also available and more are in clinical trials. Furthermore, anti-VEGF treatment (ranibizumab, aflibercept) is used as intravitreal injections to reduce the pathogenic neovascularization in wet age-related macular degeneration. iLite mVEGF Target Assay Ready Cells can be used for assessing the possibility of an anti-VEGF antibody drug inducing ADCC.

Discover the Benefits of iLite


Frequently Asked Questions

Frequently Asked Questions


Product Citations